METFORMIN EFFECTS ON CLOMIFENE-INDUCED OVULATION IN THE POLYCYSTIC OVARY SYNDROME

##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Vol. 87 No. 1 (2009): Issue Jan 2009

##plugins.themes.academic_pro.article.main##

Ben Ayed B.
Department of Obstetrics & Gynaecology CHU Hedi Chaker-Sfax
Dammak dit Mlik S
Animal physiology and cellular biology laboratory faculty of Pharmacy- Monastir
Ben Arab H
Department of Obstetrics & Gynaecology CHU Hedi Chaker-Sfax
Trabelssi H
Department of Obstetrics & Gynaecology CHU Hedi Chaker-Sfax
Chahtour H.
Department of Obstetrics & Gynaecology CHU Hedi Chaker-Sfax
Mathlouthi N
Department of Obstetrics & Gynaecology CHU Hedi Chaker-Sfax
Dhuib M
Department of Obstetrics & Gynaecology CHU Hedi Chaker-Sfax
Kassis M.
Preventive medicine laboratory faculty of Medicine- Sfax
Saiidane D.
Animal physiology and cellular biology laboratory faculty of Pharmacy- Monastir
Trabelssi K
Department of Obstetrics & Gynaecology CHU Hedi Chaker-Sfax
Guermazi M.
Department of Obstetrics & Gynaecology CHU Hedi Chaker-Sfax

Abstract

Background: Polycystic ovary syndrome (PCOS) is a common, complex endocrine disorder for women on reproductive age. A high incidence of ovulation failure is observed in PCO women and perhaps linked to insulin resistance related to metabolic features In the last few years some studies assessed hyperinsulinimea and insulin resistance attenuation effects, by insulin sensitizing agents such as metformin, in PCOS women suggesting potential scope for these drugs in CC ovulation induction quality improvement.
Aim : Our prospective study aim is to compare the effectiveness of clomifene citrate plus metformin and clomifene citrate plus placebo in women with newly diagnosed polycystic ovary syndrome.
Methods: From February 24 to September 29 (2007), PCOS was explored on women attending the Department of Obstetrics & Gynaecology sterility consultation unit (CHU Hedi Chaker-Sfax) according to the Rotterdam 2003 diagnostic criteria. PCOS patients were randomized to receive, in addition to clomifene citrate treatment, placebo or metformin 850 mg two times a day all ovulatory cycle for three trials maximum. Ovulation detection was done by the E2 serum measurements and ovarian transvaginal ultrasonography’ evolution controlling on 7th, 11th and 13th day of the cycle.
Results: Within 7 months, 32 PCOS women were recruited in the study and equally allocated to the two groups. Baseline characteristics were similar in metformin group and placebo one. Ovulation was characterized by the presence of at least one mature follicle (>16mm), a circulating estradiol concentration in the edge of
150-250pg and accessory an endometrial depth >8mm. The ovulation rate in the metformin group was 62.5% compared with 37.5% in the placebo group, a non-statistically significant (small study population) but important difference (1.66 times). Analyses show a higher mature follicle number and estradiol  concentration in metformin group than in the placebo one. Metformin effect was, in our study, his only insulinosensitizer property consequence far away a ‘making thinner’ or Hyperandrogenism reducing ones.
Conclusion: The ovulatory response to clomifene can be increased in polycystic ovary syndrome women by decreasing insulin secretion with metformin.

Keywords:

Polycystic ovary syndrome, incuded ovulation, Metformine

##plugins.themes.academic_pro.article.details##

References

  1. Fauser B, Tarlatzis B, Chang J, Azziz R, Legro R, Dewailly D, et al. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7
  2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev.1997; 18:774-800.
  3. Robert K., Bogusaw O., Anna G.D., Zbigniew S.H.: Update on the management of polycystic ovary syndrome. Pharmacological Reports, 2006, 58, 614-625
  4. Pasquali, R. and Filicori, M.Insulin sensitizing agents and polycystic ovary syndrome. Eur. J. Endocrinology, 1998 ; 138, 253-254
  5. Moran LJ, Brinkworth G, Noakes M, Norman RJ: Effects of lifestyle modification in polycystic ovarian syndrome. Reprod Biomed Online, 2006; 12: 569-578.
  6. Dewailly D.: What's new? PCO?. Reproduction humaine et hormones, 1999; 8:658-665
  7. Baillargeon JP, Iuorno MJ, Nestler JE: Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol, 2003; 46: 325-340.
  8. Glueck CJ, Goldenberg N, Streicher P, Wang P: Metformin and gestational diabetes. Curr Diab Rep, 2003; 3: 303-312.
  9. Homburg R: Clomiphene citrate - end of an era? Hum Reprod, 2005, 20, 2043-2051
  10. Baillargeon JP: Use of insulin sensitizers in polycystic ovarian syndrome. Curr Opin Investig Drugs, 2005; 6: 1012-1022.
  11. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75: 310-5
  12. Kocak M, Caliskan E, Simsir C, Haberal A.: Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrateresistant women with polycystic ovary syndrome. Fertil Steril 2002;77: 101-6
  13. Malkawi HY, Qublan HS. : The effect of metformin plus clomiphene citrate on ovulation and pregnancy rates in clomiphene-resistant women with polycystic ovary syndrome. Saudi Med J 2002; 23: 663-6.
  14. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R.: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338: 1876-80.
  15. El-Biely MM and Habba M.: The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertil Soc J 2001; 6: 43-9
  16. Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F:. Effect of clomiphene citrate plus metformin and clomiphene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 2006; 332:1485
  17. Hung Yu Ng E., Ming Sun Wat N., Chung Ho P.: Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomipheneresistant polycystic ovaries: Arandomized, double-blinded placebo-controlled trial. Hum Reprod 2001; 16: 1625-31
  18. Sturrock ND, Lannon B, Fay TN.: Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice. Br J Clin Pharmacol 2002; 53: 469-7343-9.
  19. Glueck CJ, Streicher P, Wang P: Treatment of polycystic ovary syndrome with insulin-lowering agents. Expert Opin Pharmacother, 2002; 3: 1177-1189.
  20. Heard MJ, Pierce A, Carson SA, Buster JE.: Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril, 2002; 77: 669-73
  21. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Roberts KA, Nestler JE. : Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 2002; 87: 524-9
  22. Essah PA, Nestler JE: The metabolic syndrome in polycystic ovary syndrome. J Endocrinol Invest, 2006; 29: 270-280.
  23. Simmons D, Walters BN, Rowan JA, McIntyre HD: Metformin therapy and diabetes in pregnancy. Med J Aust, 2004; 180: 462-464
  24. Goodarzi MO and Korenman SG: The importance of insulinresistance in polycystic ovary syndrome. Fertil Steril, 2003; 80: 255-258.
  25. Diamanti-Kandarakis E, Papailiou J, Palimeri S: Hyperandrogenemia: pathophysiology and its role in ovulatory dysfunction in PCOS. Pediatr Endocrinol Rev, 2006; 3 (Suppl 1): 198-204
  26. Seli E, Duleba AJ: Treatment of PCOS with metformin and other insulinsensitizing agents. Curr Diab Rep, 2004; 4: 69-75.
  27. Pritts EA: Treatment of the infertile patient with polycystic ovarian syndrome. Obstet Gynecol Surv, 2002; 57: 587-597.
  28. Germond M., Gaillard M.C., Senn A. : Syndrome d'hyperstimulation ovarienne. Archives of gynecology and obstetrics, 2005; 246: 53
  29. Maciel GAR, Junior JMS, Motta ELA, Haida MA, Lima GR and Baracat EC: Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril . 2004; 81:355-360
  30. Tang T., Glanville J., Hayden C.J., White D., Barth J.H., Balen A.H.: Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Human Reproduction, 2006; 21:80-89
  31. Wong LL and Wong TC : Metformin induced anorexia and weight loss. Hawaii Med J, 2003; 62:104-5
  32. Siraj ES : Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes? Cleve Clin J Med, 2003; 70:702-704
  33. Kolodziejczyk B., Duleba, A.J., Spaczynski, R.Z.: Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil. Steril.,2000; 73: 1149-1154
  34. Nestler JE, Jakubowicz DJ.: Decreases in ovarian cytochrome P450c17activity and serum free testosterone after reduction in insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996;335:617-623
  35. Crave J.C, Fimbel S., Lejeune H., Cugnardey N., Dechaud H., Pugeat M.: effects of diet and metformin administration on sex hormone-bindingglobulin, androgens and insulin in hirsute and obese women. J Clin Endocrinol Metab, 1995;80 : 2057-62.
  36. KS.: Effects of metformin on insulin secretion, insulin action and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab.1997; 82:524-530
  37. Faddy MI, Gosden RG, Gougeon A, Richardson SJ, Nelson JF.: Accelerated disappearance of ovarian follicles in midlife: implications for forecasting menopause. Hum Reprod, 1992; 7: 1342 - 1346.
  38. FIVNAT : Procréations médicalement assistées à 40 ans. Contracept Fertil Sex, 1990;18: 595